In vivo 18F‐fluoride‐PET imaging reveals pronounced heterogeneity in bone formation in multiple myeloma patients
J. Regelink,G. Zwezerijnen,R. Groen,S. Zweegman,P. Raijmakers
DOI: https://doi.org/10.1111/bjh.18588
2022-12-08
British Journal of Haematology
Abstract:Bone resorption by activated osteoclasts is a hallmark of multiple myeloma (MM) bone disease. Myeloma cells reduce osteoprotegerin (OPG) levels by binding, internalisation, and degradation of OPG, which is mediated by syndecan1 being expressed on the cell surface of myeloma cells. As OPG is known to inhibit the interaction between RANK and RANKL, a reduction in OPG will lead to activation of the RANK/RANKL pathway with an activation of osteoclasts as a result. In addition, activation of the Notchsignalling pathway in the myeloma cells results in production of RANKL, further enhancing osteoclast activity.1 Besides bone resorption, impaired bone formation is presumed to play a role in MM bone disease. Myeloma cells express sclerostin, Dickkopf1 and soluble frizzledrelated proteins, antagonising Wnt signalling, which leads to apoptosis of osteoblasts and restriction of osteoblast maturation, ultimately impairing bone mineralisation.2 However, in contrast, in vivo mouse experiments have shown that inoculation of MM cells initially induces recruitment and cell cycling of mesenchymal stem cells (MSC) and preosteoblasts.3,4 Accordingly, in patients, recruitment of osteoblasts has been observed early in the course of the disease.5 Recently, we described the results of in vivo bone formation using 18FfluoridePET (positron emission tomography), a technique from which we proved that it correlated with the gold standard for bone formation, the Mineral Apposition Rate (MAR). Using this technique, we showed that the 18Ffluoride uptake in the individual osteolytic lesions appeared to be heterogeneous, between, as well as within patients.6 A plausible explanation for this heterogeneity might be that an intimate spatial interaction between MM and bone cells in bone formation is required in order to affect bone formation. In order to further unravel this, we here present an indepth analysis of bone formation in five patients of whom details of disease characteristics, treatment and imaging methods were previously reported.6 In summary, five bortezomibnaïve MM patients with relapsed disease were treated with bortezomib monotherapy without dexamethasone, which was standard of care at the time the study was performed and based on the APEX trial.7 Starting treatment with bisphosphonates was not allowed for patients during the study. Only patients who were on bisphosphonates for more than three months were allowed to be included in the study, provided that treatment was continued throughout the study (one out of five patients). 18FfluoridePET and 18Ffluorodeoxyglucose (FDG) PET scans were performed before and after four cycles of therapy. Bone disease, defined as an osteolytic lesion on computed tomography (CT) that was metabolically active on 18FFDGPET, was present in all five patients. In one patient, bone disease was also characterised by a new lesion on magnetic resonance imaging (MRI; patient 5). Twentyfive 18Ffluoridepositive lesions were identified in all five patients (range 2– 9 per patient). Received: 1 August 2022 | Accepted: 22 November 2022
Medicine